These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19691928)

  • 41. B cells and atherosclerosis in systemic lupus erythematosus.
    Koulouri V; Koutsilieris M; Mavragani CP
    Expert Rev Clin Immunol; 2019 Apr; 15(4):417-429. PubMed ID: 30652925
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Accelerated artherosclerosis in systemic lupus erythematosus patients and the role of some adipocytokines in this process].
    Hrycek E; Banasiewicz-Szkrobka I; Żurakowski A; Buszman P
    Wiad Lek; 2016; 69(6):778-785. PubMed ID: 28214815
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Premature vascular damage in systemic lupus erythematosus.
    Kaplan MJ
    Autoimmunity; 2009 Nov; 42(7):580-6. PubMed ID: 19657770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis.
    Reiss AB; Wan DW; Anwar K; Merrill JT; Wirkowski PA; Shah N; Cronstein BN; Chan ES; Carsons SE
    Exp Biol Med (Maywood); 2009 Mar; 234(3):354-60. PubMed ID: 19144874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of the vasculature: clues from lupus.
    Merrill JT
    Curr Opin Rheumatol; 2002 Sep; 14(5):504-9. PubMed ID: 12192245
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus.
    Stanic AK; Stein CM; Morgan AC; Fazio S; Linton MF; Wakeland EK; Olsen NJ; Major AS
    Proc Natl Acad Sci U S A; 2006 May; 103(18):7018-23. PubMed ID: 16636270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin.
    Hahn BH; Lourencço EV; McMahon M; Skaggs B; Le E; Anderson M; Iikuni N; Lai CK; La Cava A
    Lupus; 2010 Jul; 19(8):913-7. PubMed ID: 20410156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic lupus erythematosus and atherosclerosis: Review of the literature.
    Frieri M; Stampfl H
    Autoimmun Rev; 2016 Jan; 15(1):16-21. PubMed ID: 26299985
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis.
    George J; Harats D; Gilburd B; Levy Y; Langevitz P; Shoenfeld Y
    Lupus; 1999; 8(3):220-6. PubMed ID: 10342715
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Premature coronary-artery atherosclerosis in systemic lupus erythematosus.
    Asanuma Y; Oeser A; Shintani AK; Turner E; Olsen N; Fazio S; Linton MF; Raggi P; Stein CM
    N Engl J Med; 2003 Dec; 349(25):2407-15. PubMed ID: 14681506
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Traditional and nontraditional risk factors for atherosclerosis in patients with systemic lupus erythematosus.
    Pompilian V; Badea C; Dragomanu I; Bălăşescu E; Tănăsescu C
    Rom J Intern Med; 2008; 46(3):195-8. PubMed ID: 19366077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
    Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
    Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies.
    Robinson G; Pineda-Torra I; Ciurtin C; Jury EC
    J Clin Invest; 2022 Jan; 132(2):. PubMed ID: 35040437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis.
    Baumer Y; Ng Q; Sanda GE; Dey AK; Teague HL; Sorokin AV; Dagur PK; Silverman JI; Harrington CL; Rodante JA; Rose SM; Varghese NJ; Belur AD; Goyal A; Gelfand JM; Springer DA; Bleck CK; Thomas CL; Yu ZX; Winge MC; Kruth HS; Marinkovich MP; Joshi AA; Playford MP; Mehta NN
    JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321372
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Premature atherosclerotic disease in systemic lupus erythematosus--role of inflammatory mechanisms.
    Rhew EY; Ramsey-Goldman R
    Autoimmun Rev; 2006 Feb; 5(2):101-5. PubMed ID: 16431336
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.
    Kahlenberg JM; Kaplan MJ
    Arthritis Res Ther; 2011 Feb; 13(1):203. PubMed ID: 21371346
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inflammatory lipids as a target for therapy in the rheumatic diseases.
    McMahon M; Brahn E
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1213-24. PubMed ID: 18616417
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship.
    Sciatti E; Cavazzana I; Vizzardi E; Bonadei I; Fredi M; Taraborelli M; Ferizi R; Metra M; Tincani A; Franceschini F
    Curr Rheumatol Rev; 2019; 15(3):177-188. PubMed ID: 30474532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dyslipidemia in systemic lupus erythematosus: just another comorbidity?
    Tselios K; Koumaras C; Gladman DD; Urowitz MB
    Semin Arthritis Rheum; 2016 Apr; 45(5):604-10. PubMed ID: 26711309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of Cholesterol Metabolism in Immune Cell Function and Atherosclerosis.
    Aguilar-Ballester M; Herrero-Cervera A; Vinué Á; Martínez-Hervás S; González-Navarro H
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32645995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.